CJC-1295 (No DAC) vs GHRP-6
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: CJC-1295 DAC, CJC-1295 no DAC
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), specifically a modified GHRH(1-29), engineered for a long duration of action. The form most people mean by CJC-1295 includes a Drug Affinity Complex (DAC) that binds blood albumin to extend its half-life to roughly 6 to 8 days, raising GH and IGF-I for days from a single injection. It was developed by ConjuChem, reached Phase II trials and was abandoned; it is not an approved drug and is sold only as a research chemical. A version without DAC (Modified GRF 1-29) acts for only about 30 minutes.
Also: Growth Hormone Releasing Peptide 6, SKF-110679
GHRP-6 is a synthetic six-amino-acid peptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) that tricks the body into releasing its own growth hormone. It was one of the first growth hormone secretagogues ever made, and the hunt to find out why it worked led scientists straight to the discovery of ghrelin. It has no approval as a drug anywhere and is used only as a research compound.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- These GH secretagogues are frequently combined to enhance growth hormone release.
Detailed Comparison
| Attribute | CJC-1295 (No DAC) | GHRP-6 |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | CJC-1295 acts at the GHRH receptor on pituitary somatotroph cells, the same receptor the body's own GHRH uses, prompting the pituitary to synthesize and release growth hormone. Native GHRH is broken down within minutes; CJC-1295 with DAC carries a reactive group that covalently bonds to circulating albumin after injection, shielding it from breakdown and stretching its half-life from minutes to days. The sustained GH elevation drives the liver to produce IGF-I, the downstream hormone behind many of GH's tissue effects. There are two versions: with DAC (long-acting, albumin-binding) and without DAC (Modified GRF 1-29), which lacks the albumin tether. Because it works through the pituitary, it relies on the gland's own GH-producing capacity. | GHRP-6 binds and activates the growth hormone secretagogue receptor type 1a (GHS-R1a), the same receptor later found to be the natural target of the hunger hormone ghrelin. When it switches that receptor on in the pituitary and hypothalamus, the pituitary fires off a pulse of growth hormone. Because GHS-R1a also sits on appetite-driving neurons in the brain (the NPY/AgRP cells of the arcuate nucleus), GHRP-6 is a strong appetite stimulant, more so than the other GHRPs. At higher doses it also nudges up cortisol and prolactin, since the receptor system is not perfectly selective for the GH pathway. |
| Common Dosing | 100 mcg daily (no DAC) or 2 mg weekly (with DAC) Daily (no DAC) or 1-2x weekly (with DAC) | 100-300 mcg 2-3x daily 2-3x daily |
| Administration | Subcutaneous injection | Subcutaneous injection, ideally fasted |
| Typical Duration | 8-12 weeks | 8-12 weeks |
| Best Time to Take | Before bed | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The key human study is Teichman et al. (2006) in the Journal of Clinical Endocrinology and Metabolism, a randomized, double-blind, placebo-controlled ascending-dose trial in healthy adults. A single subcutaneous injection raised mean plasma GH 2- to 10-fold for 6 days or more and IGF-I 1.5- to 3-fold for 9 to 11 days, with cumulative effects on repeat dosing, and was reported as safe and relatively well tolerated short-term. An earlier study showed once-daily CJC-1295 normalized growth in GHRH-knockout mice. Beyond pharmacokinetics and hormone levels, there are no large long-term human trials demonstrating clinical benefits like fat loss or muscle gain, so those claims are not established by published trials. Development was halted after Phase II; a single trial death was attributed by the attending physician to pre-existing coronary artery disease rather than the drug, which is reported but not independently confirmed. Bottom line: the GH and IGF-I-raising effect and long half-life are well supported, while real-world efficacy and long-term safety are not. | GHRP-6 has been studied in humans, but mostly as a lab and diagnostic probe rather than as a treatment with large clinical trials behind it. Early work in the 1980s and 1990s showed it reliably triggers growth hormone release, and chasing its mechanism is literally what led Kojima and colleagues to discover ghrelin in 1999, which reframed how we understand hunger and GH control. A 2013 pharmacokinetic study in nine healthy men found oral bioavailability under 1 percent and an elimination half-life around 2.5 hours, which is why it is given by injection. The popular claims about muscle gain, fat loss, and healing in fitness circles are not backed by controlled human outcome trials. It is not approved by the FDA or EMA for any use and remains a research chemical, with appetite stimulation, water retention, and cortisol/prolactin bumps as known effects. |
Frequently Asked Questions: CJC-1295 (No DAC) vs GHRP-6
What is the difference between CJC-1295 (No DAC) and GHRP-6?
CJC-1295 (No DAC) is a growth hormone peptide that cjc-1295 is a synthetic analog of growth hormone-releasing hormone (ghrh), specifically a modified ghrh(1-29), engineered for a long duration of action. the form most people mean by cjc-1295 includes a drug affinity complex (dac) that binds blood albumin to extend its half-life to roughly 6 to 8 days, raising gh and igf-i for days from a single injection. it was developed by conjuchem, reached phase ii trials and was abandoned; it is not an approved drug and is sold only as a research chemical. a version without dac (modified grf 1-29) acts for only about 30 minutes. GHRP-6 is a growth hormone peptide that ghrp-6 is a synthetic six-amino-acid peptide (his-d-trp-ala-trp-d-phe-lys-nh2) that tricks the body into releasing its own growth hormone. it was one of the first growth hormone secretagogues ever made, and the hunt to find out why it worked led scientists straight to the discovery of ghrelin. it has no approval as a drug anywhere and is used only as a research compound. The main differences lie in their mechanisms of action and clinical applications.
Which is better, CJC-1295 (No DAC) or GHRP-6?
Neither is universally "better" - the choice depends on your specific goals. CJC-1295 (No DAC) is typically used for growth hormone purposes, while GHRP-6 is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can CJC-1295 (No DAC) and GHRP-6 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using CJC-1295 (No DAC) and GHRP-6 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.